The Rho-associated kinase inhibitor fasudil can replace Y-27632 for use in human pluripotent stem cell research

Seongjun So, Yeonmi Lee, Jiwan Choi, Seoon Kang, Ji Yoon Lee, Julie Hwang, Joosung Shin, James R. Dutton, Eul Ju Seo, Beom Hee Lee, Chong Jai Kim, Shoukhrat Mitalipov, Soo Jin Oh, Eunju Kang

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Poor survival of human pluripotent stem cells (hPSCs) following freezing, thawing, or passaging hinders the maintenance and differentiation of stem cells. Rho-associated kinases (ROCKs) play a crucial role in hPSC survival. To date, a typical ROCK inhibitor, Y-27632, has been the primary agent used in hPSC research. Here, we report that another ROCK inhibitor, fasudil, can be used as an alternative and is cheaper than Y-27632. It increased hPSC growth following thawing and passaging, like Y-27632, and did not affect pluripotency, differentiation ability, and chromosome integrity. Furthermore, fasudil promoted retinal pigment epithelium (RPE) differentiation and the survival of neural crest cells (NCCs) during differentiation. It was also useful for single-cell passaging of hPSCs and during aggregation. These findings suggest that fasudil can replace Y-27632 for use in stem research.

Original languageEnglish (US)
Article numbere0233057
JournalPloS one
Volume15
Issue number5
DOIs
StatePublished - May 2020

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'The Rho-associated kinase inhibitor fasudil can replace Y-27632 for use in human pluripotent stem cell research'. Together they form a unique fingerprint.

Cite this